CDH1 and neoplasm: The potential of this therapeutic approach using CRISPR-Cas9 based gene editing has demonstrated promising results harnessing druggable vulnerabilities in CDH1-mutant cancers and profound anti-tumour effects in multiple studies as detailed in Table 1 [67–73].